Volker Schellenberger

Volker Schellenberger

Company: Amunix Pharmaceuticals

Job title: President & Chief Executive Officer


Widening the Therapeutic Index of IL12 Using Protease- Cleavable XTEN Masks 3:00 pm

• Learn how we generated IL12-XPAC (XTENylated Protease Activated Cytokine) utilizing XTEN protein polymers • Explore XTEN serving as a protease releasable steric mask that increases plasma half-life while reducing off tumor activity • Delve into IL12-XPAT showing significantly increased potency and reduced toxicity in murine xenograft modelsRead more

day: Day One

Formal Closing Panel Discussion: Predicting Future Directions For Cytokine Therapeutic Development & Treatment 5:00 pm

Read more

day: Day Two

Breakfast Panel: What Do We Know & Where Do We Want to Go? 7:40 am

How can we learn from successes and shortfalls of the previous cytokine era Where have the current engineering strategies taken us? Reflecting back on what we learned in the previous cytokine era Assessing the latest clinical work with lesser known/used cytokines Considerations for moving current promising pre-clinical data into the clinic Combinations? Where is there…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.